Newsroom

December 2018

• Press release Dec 19, 2018

  Alcon Announces Acquisition of Tear Film Innovations, Inc.

  Acquisition further expands Alcon's portfolio of comprehensive solutions for patients with dry eye Tear Film's iLux® Device offers innovative, customizable treatment for Meibomian Gland…
• Press release Dec 13, 2018

  Novartis receives European Commission approval for self-administration of Xolair® across all indications

  The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe[1]   Xolair® (omalizumab) prefilled…
• 
  Story Dec 12, 2018 Discovery

  Women in Science: Susanne Schaffert

  Susanne Schaffert, President of Advanced Accelerator Applications, describes her career in science.

• 
  Story Dec 12, 2018 Discovery

  Bringing real change to people

  An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.

• Press release Dec 10, 2018

  Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder

  reSET-OTM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two…
• 
  Story Dec 10, 2018 Patient Perspectives

  The changing landscape of cancer treatment

• Press release Dec 08, 2018

  Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

   Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine…
• 
  Story Dec 07, 2018 Access to Healthcare

  Improving lives through community-based care

  Bringing healthcare closer to where people live, work and shop can effectively tackle hypertension – the most deadly noncommunicable disease.

• Press release Dec 06, 2018

  Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses

  BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor…
• 
  Story Dec 05, 2018 Discovery

  From patient to patient advocate: how a cancer diagnosis fueled a new career path

  Elyse Spatz Caplan’s cancer diagnosis impacted her life in more ways than 1

• Press release Dec 04, 2018

  Novartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head data

  PEARL 1 and PEARL 2, the largest pivotal trials to date in chronic spontaneous urticaria (CSU), will enroll more than 2,000 CSU patients[1],[2]   Ligelizumab (QGE031), a monoclonal antibody…
• Press release Dec 03, 2018

  Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1

  The AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx)[1], filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative…